Pricing and Reimbursement
Bold politics – what about the economics?: An overview of President Trump’s ‘Most Favoured Nation’ Executive Order
2 June 2025
This is the first in a series of OHE Insights on the history, implications and possible impact of President Trump’s Executive Order on a “Most Favoured Nation” (MFN) pricing model for pharmaceuticals.
R&D for new drugs to tackle AMR is a high-return investment for all EU member states
19 July 2024
Two recently-published papers predict high returns from a policy which incentivises the development of new antibiotics.
OHE’s AMR consultation response
21 November 2023
This blog summarises our perspective on the recent proposals set out by NHS England to assess the value of new antibiotics via a new scoring system linked to a volume-delinked revenue guarantee payment. Key arguments outlined here were submitted to NHS England as part of OHE’s response to the consultation on proposals.
Setting the Right Discount Rate for HTA in the Slovak Republic
21 May 2023
Health interventions such as new medicines produce costs and health-related effects not only in the year they are introduced but in all future years until they…
Real-World Evidence: Current Best Practice for Reimbursement Decision-Making
15 May 2023
In this report, we discuss best practices for RWE generation and the steps needed to enhance the assessment and use of quality RWE in reimbursement decisions.
New free educational program launched – Explaining the U.S. Inflation Reduction Act
9 May 2023
We have launched a free online explainer to the U.S. Inflation Reduction Act. It makes essential viewing for anyone wanting a sound knowledge of the technical detail of the Act and how it relates to pharmaceutical payment and coverage.
How Restrictive are NICE ‘Optimised’ Decisions?
27 April 2023
NICE makes ‘optimised’ decisions to support use of medicines in smaller groups of patients. Between 2020 to 2022, 56% of optimised decisions recommended treatment for less than half of eligible patients.
Delivering the Triple Win: A Value-Based Approach to Pricing
20 April 2023
In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of value-based pricing can be enhanced to deliver the triple win of patient access; healthcare system sustainability; and innovation.
Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges
6 February 2023
During an engaging discussion of Professor Aidan Hollis’ prizewinning proposal with Professor Adrian Towse a range of potential benefits and remaining questions were explored.